Voyager Therapeutics (NASDAQ:VYGR - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a report issued on Thursday, Benzinga reports. They presently have a $30.00 price objective on the stock. HC Wainwright's target price points to a potential upside of 356.27% from the company's previous close.
VYGR has been the topic of several other research reports. Leerink Partners assumed coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They set an "outperform" rating and a $15.00 price objective on the stock. Leerink Partnrs upgraded shares of Voyager Therapeutics to a "strong-buy" rating in a report on Wednesday, October 16th. StockNews.com upgraded shares of Voyager Therapeutics from a "hold" rating to a "buy" rating in a report on Friday, October 11th. Finally, Wedbush dropped their price objective on shares of Voyager Therapeutics from $8.00 to $7.00 and set a "neutral" rating on the stock in a report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Voyager Therapeutics has a consensus rating of "Buy" and a consensus target price of $17.43.
Read Our Latest Report on Voyager Therapeutics
Voyager Therapeutics Trading Up 2.3 %
VYGR traded up $0.15 during trading on Thursday, hitting $6.58. The stock had a trading volume of 558,098 shares, compared to its average volume of 646,116. The firm has a market cap of $357.64 million, a PE ratio of -131.50 and a beta of 0.91. Voyager Therapeutics has a 12 month low of $5.71 and a 12 month high of $11.72. The company has a 50 day simple moving average of $6.55 and a 200-day simple moving average of $7.64.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.20. The firm had revenue of $29.58 million for the quarter, compared to the consensus estimate of $11.52 million. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. During the same quarter last year, the firm posted ($0.51) EPS. As a group, sell-side analysts anticipate that Voyager Therapeutics will post -1.27 earnings per share for the current fiscal year.
Insider Activity at Voyager Therapeutics
In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company's stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now owns 86,001 shares of the company's stock, valued at $500,525.82. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.53% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Voyager Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC boosted its position in Voyager Therapeutics by 11.3% in the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company's stock valued at $41,132,000 after buying an additional 528,000 shares in the last quarter. Vanguard Group Inc. boosted its position in Voyager Therapeutics by 27.8% in the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company's stock valued at $30,087,000 after buying an additional 702,030 shares in the last quarter. Farallon Capital Management LLC boosted its position in Voyager Therapeutics by 77.4% in the first quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company's stock valued at $21,339,000 after buying an additional 1,000,000 shares in the last quarter. Great Point Partners LLC acquired a new position in Voyager Therapeutics in the second quarter valued at about $12,668,000. Finally, Price T Rowe Associates Inc. MD boosted its position in Voyager Therapeutics by 3.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company's stock valued at $9,702,000 after buying an additional 37,144 shares in the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.
About Voyager Therapeutics
(
Get Free Report)
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
Further Reading
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
